Comparative Analysis of Adult Patients With Idiopathic Pulmonary Hemosiderosis and Lane-Hamilton Syndrome: A Systematic Review of the Literature in the Period 1971-2022

Biplab K. Saha 1, Praveen Datar 1, Alexis Aiman 2, Alyssa Bonnier 3, Santu Saha 4, Nils T. Milman 5

1. Pulmonary and Critical Care Medicine, Ozarks Medical Center, West Plains, USA
2. Internal Medicine, New York Institute of Technology College of Osteopathic Medicine at Arkansas State University, Jonesboro, USA
3. Critical Care, Goldfarb School of Nursing at Barnes Jewish College, Saint Louis, USA
4. Internal Medicine, Saha Clinic, Narail, BGD
5. Pulmonary and Critical Care, University College Zealand, Næstved, DNK

Corresponding author: Biplab K. Saha, spanophiliac@yahoo.com

Abstract

Idiopathic pulmonary hemosiderosis (IPH) causes diffuse alveolar hemorrhage (DAH) by a yet unknown mechanism. The coexistence of IPH and celiac disease (CD), also known as Lane-Hamilton syndrome (LHS), has been reported in both pediatric and adult patients. The objective of this study was to compare demographics, clinical and radiologic findings, treatment, and outcomes between adult patients with IPH and LHS.

This is a systematic review of the literature. Multiple databases were searched using appropriate formulas to identify relevant articles. A total of 60 studies reporting 65 patients were included in the review. Forty-nine of these patients had IPH and 16 had LHS. The prevalence of anti-CD antibodies among tested patients was 13/22 (59%). The symptom onset and diagnosis of IPH occurred earlier in patients with LHS. The median delay in diagnosis was the same between the two groups (52 weeks). The classic triad was more likely to be present in patients with LHS. Only 20% of patients in the LHS cohort had any significant gastrointestinal (GI) symptoms at the time of IPH diagnosis. A gluten-free diet alone was effective in the majority of patients. Fewer patients in the LHS cohort received systemic corticosteroid than the IPH cohort. The recurrence and mortality in patients with LHS appear to be less than in the IPH cohort. The prevalence of CD is 25% in adult patients with IPH. Patients with LHS may have a milder course than patients without CD. Serologic testing for CD should be performed in all patients diagnosed with IPH.

Introduction And Background

Idiopathic pulmonary hemosiderosis (IPH) is a rare disease that only affects the lungs. IPH causes diffuse alveolar hemorrhage (DAH) by an unknown mechanism and is often recurrent. An appropriate diagnosis of IPH requires careful exclusion of all competing diagnoses and histopathologic proof of "bland pulmonary hemorrhage"[1-4]. The histopathologic hallmark of IPH includes evidence of recent and/or prior alveolar hemorrhage, extracellular or intracellular deposition of hemosiderin in the alveolar macrophages, type 2 pneumocyte hyperplasia, and the absence of necrosis, vasculitis, granulomatosis, immunocomplex deposition, or inflammatory cellular infiltration of the pulmonary interstitium [5-6]. The repeated episodes of pulmonary hemorrhage result in local iron overload, causing pulmonary hemosiderosis. Additionally, chronic oxidative damage by heme and free radicals may result in pulmonary fibrosis, chronic respiratory impairment, or even end-stage lung disease [7-10].

Celiac disease (CD) is a common autoimmune disease with well-known intestinal and extraintestinal manifestations. The coexistence of IPH and CD, also known as Lane-Hamilton syndrome (LHS), was first reported by Drs. Lane and Hamilton more than 50 years ago [11]. Whether this is a mere coincidence, or an underlying unifying pathobiology exists, is unknown. It is also unclear if there is any difference regarding demographics, clinical presentations, and prognosis between patients with IPH and LHS. Anecdotally, some authors have reported positive outcomes with a gluten-free diet (GFD) without immunosuppression in patients with LHS, but there have been no prospective or retrospective studies to address these questions.

In this manuscript, we have performed a thorough review of the literature to elucidate the similarities and differences between adult patients with IPH and LHS.

Review

Materials and methods

How to cite this article
Saha B K, Datar P, Aiman A, et al. (March 25, 2022) Comparative Analysis of Adult Patients With Idiopathic Pulmonary Hemosiderosis and Lane-Hamilton Syndrome: A Systematic Review of the Literature in the Period 1971-2022. Cureus 14(3): e23482. DOI 10.7759/cureus.23482
This is a systematic review of the existing literature. The review was performed and reported according to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines [12].

Creation of Patient Cohorts

The Medline, PubMed, and Embase databases were searched using the following formula:

'Idiopathic pulmonary hemosiderosis OR IPH AND adults'; 'idiopathic pulmonary hemosiderosis OR IPH AND celiac disease'; 'idiopathic pulmonary hemosiderosis OR IPH AND celiac disease'; and 'idiopathic pulmonary hemosiderosis OR IPH AND celiac disease AND adult.' Two independent investigators (BKS and AB) abstracted each identified study and compared their results. The reviewers were blinded to each other's assessment. Any disagreement between the researchers was resolved by discussion and input from a third investigator, SS. After the citations were identified, we removed duplicate citations. We then screened the abstract of each citation for applicability to our review. Citations that were deemed unrelated to our research after an independent evaluation of the abstract by the reviewers were excluded. The full texts of the remaining citations were then reviewed, along with a careful examination of the bibliography of the published articles. The identified patients were then divided into two cohorts: 1) adult patients with IPH without CD, cohort A, and 2) Adult patients with LHS, cohort B. Strict inclusion and exclusion criteria were followed while identifying patients with IPH from the literature.

Study Objectives

The primary objectives of the study were to compare the following parameters between adult IPH patients with (LHS) or without CD: 1) demographics, 2) age at symptom onset, 3) age at diagnosis, 4) duration between symptom onset and diagnosis of IPH, 5) clinical presentation, 6) radiologic abnormalities, 7) treatment, and 8) prognosis and survival.

The secondary objectives were to report histopathologic findings from small bowel biopsy and non-pulmonary organ involvements in patients with LHS.

Inclusion Criteria

Strict inclusion criteria were followed during the selection of appropriate studies. Articles fulfilling the following criteria were included in this review: 1) prospective or retrospective studies that reported the occurrence of IPH in patients age 18 and above; 2) case reports or case series that reported patients with LHS; 3) cases where the diagnosis of IPH was made with consistent clinical and radiologic findings and demonstration of hemosiderin-laden macrophages (HLM) from respiratory tract samples, obtained either by bronchoscopy or spontaneous expectoration (sputum), and/or lung biopsy consistent with IPH; 4) articles published in the English language in peer-reviewed journals between January 1, 1971, and February 21, 2022.

Exclusion Criteria

The exclusion criteria were as follows: 1) articles where the patient was diagnosed with IPH as a child, even if the patient was reported as an adult; 2) articles that reported autoantibodies, demonstrated signs and symptoms of vasculitis, and had lung or kidney biopsies consistent with vasculitis during the initial diagnosis of IPH (these patients were considered to be suffering from primary vasculitides); 3) patients with bland pulmonary hemorrhage with clinical and laboratory findings diagnostic of a connective tissue disease during initial diagnosis (pulmonary hemorrhage in these patients were determined to be secondary to the rheumatologic disease and the patient was not labeled with IPH), however, if a patient with biopsy-proven IPH developed a connective tissue disease years later, the patient was included, as the causation could not be proven definitively; 4) pediatric patients with IPH and autoantibodies; these have been reported in a recent paper [13]; 5) patients reported as meeting abstracts; 6) patients reported in a non-English language.

Data Items

Included studies were coded, and the extracted data from the studies were then tabulated in a standardized Excel sheet (Microsoft Corporation, Redmond, WA). The following data were gathered from all full-text articles: study design, year of reporting, country of the study, patient demographics, presenting symptoms, delay in the diagnosis of IPH, types of tested autoantibodies, type of positive autoantibodies, the temporal relationship of autoantibody determination with the diagnosis of IPH, diagnostic modality, lung biopsy results when available, treatment, and clinical outcome of the disease. Additional data were collected relevant to CD for patients with LHS. These included small intestinal biopsy and evidence of other organ involvement.

Study Risk and Bias Assessment:
The risk of bias was not assessed, as the identified papers were primarily case reports and case series.

Statistical Analysis

Descriptive and inferential statistical analyses were performed using the IBM SPSS statistical software package, version 28 (IBM Corp., Armonk, NY). The normality of distribution was assessed by the Shapiro-Wilk test. Normally distributed data were reported as mean (standard deviation, SD) and median (interquartile range, IQR). Non-normally distributed data were reported only as median (IQR). The difference between the two ratio variables was measured by the independent one-way t-test and two categorical variables by the chi-square or Fisher’s exact test.

Result

Study Characteristics

A total of 60 studies that fulfilled the inclusion criteria were identified [2,11,14-69]. Figure 1 illustrates the study selection process. No prospective or retrospective studies were included for this review. We excluded a retrospective study consisting of nine patients, as the paper did not have adequate individual patient details [70]. Among the 60 studies, 55 papers were case reports that presented a single patient. The other five papers were small case series [30,36,40,64,71]. Patients were reported from all continents.

Subject Demographics

A total of 65 patients were included in this review. The patients were divided into two cohorts. Cohort A included patients with IPH without CD (49 patients). Cohort B consisted of patients with LHS and consisted of 16 patients [11,22,26-27,31,37,41,45,52-53,55-56,58-59,67,72].

FIGURE 1: Flow-chart showing the selection of studies
The median and mean age of cohort A at the time of IPH diagnosis were 27 years (IQR, 27.5) and 35.49 years (SD, 16.9), respectively. The median and mean age of cohort B at IPH diagnosis were 27 years (IQR, 17) and 26.62 years (SD, 10.04), respectively. The difference in mean age at diagnosis did not reach statistical significance (independent sample one-way t-test, p=.051).

The median and mean age at symptom onset in cohort A were 27 years (IQR, 27) and 34.33 years (SD, 17.54), respectively. The median and mean age at symptom onset were 26 years (IQR, 11) and 25.53 years (SD, 10.33), respectively, in cohort B. The difference in mean age at symptom onset was statistically significant (independent sample one-way t-test, p=.012).

Twenty-eight out of 49 (57.1%) patients were males in cohort A compared to 12/16 (75%) patients in cohort B. A detailed breakdown of the demographic data based on gender is presented in Table 1.

| Patient demographics                  | Cohort A (IPH without CD) | Cohort B (IPH with CD) | P-value |
|--------------------------------------|---------------------------|------------------------|---------|
| Age at IPH diagnosis in years        | Mean (SD)                 | Median (IQR)           | Mean (SD) | Median (IQR) |         |
| All patients                         | 35.49 (16.90)             | 27 (27.5)              | 26.62 (10.04) | 27 (17) | P=.051 |
| Male                                 | 38.46 (19.10)             | 32.5 (27.75)           | 27.5 (7.39) | 27 (13)  |         |
| Female                               | 31.46 (12.78)             | 27 (25)                | 36 (15.23) | 37 (28)  |         |
| Age at symptom onset in years        | Mean (SD)                 | Median (IQR)           | Mean (SD) | Median (IQR) |      |
| All patients                         | 34.33 (17.54)             | 27 (27)                | 25.53 (10.33) | 26 (11) | P=.012  |
| Male                                 | 36.92 (19.36)             | 30 (29)                | 24.33 (9.04) | 25.5 (11) |         |
| Female                               | 30.44 (14.03)             | 24.5 (27.5)            | 30.33 (15.94) | 26 ()  |         |
| Delay in diagnosis in weeks          | Median                    | Median                 |         |
| All patients                         | 52                        | 52                     |         |
| Male                                 | 52                        | 52                     |         |
| Female                               | 69                        | 92                     |         |
| Classic triad at presentation - percent | 74.5%                    | 93.8%                  |         |
| Immunosuppressive therapy - percent  | 80.4%                     | 40%                    |         |
| Recurrence                           | 56.8%                     | 28.6%                  | P=.086  |
| Survival                             | 88.7%                     | 100%                   | P=.098  |
| Gender - male                        | 57.1%                     | 75%                    |         |

**TABLE 1: Summary of comparative data between cohorts A and B**

IPH, idiopathic pulmonary hemosiderosis; IQR, interquartile range; SD, standard deviation

**Presenting Symptoms of IPH**

The presenting symptoms varied between cohorts A and B as follows: hemoptysis (77.6% vs 95.8%), dyspnea (83.3% vs. 81.3%), anemia (87.5% vs. 100%), cough without hemoptysis (24.5% vs. 18.8%), and chest pain (6.1% vs. 12.5%). Systemic symptoms, such as fever, night sweats, chills, fatigue, weight loss, or loss of appetite, were present in 32.7% vs. 50% of patients. Respiratory failure was reported in 8/49 (16.3%) patients in cohort A. In contrast, no patient in cohort B suffered from respiratory failure (Fischer's exact test, p=.102).

**Delay in the Diagnosis of IPH**

The median delay from onset of symptoms to diagnosis of IPH was 52 weeks for both cohorts A and B (non-normally distributed data). More detailed data are given in Table 1. The mean difference in the diagnostic delay between cohort B and A was 71.57 weeks, which was not statistically significant (p=.154).

**Laboratory and Radiologic Findings**
The mean hemoglobin on admission for cohorts A and B were 8.8 (SD, 2.59) and 7.43 (SD, 2.35) gm/dL, respectively. The mean difference was not statistically significant, p=0.088. The median serum ferritin levels were 91.85 ng/ml (IQR,117.43) for cohort A and 40.78 ng/ml (IQR, 510.61) for cohort B (non-normal data).

The radiologic findings in cohorts A and B were as follows: bilateral infiltrate (91.5% vs.100%), emphysema or cystic changes (19.1% vs. 18.8%), and interstitial changes (27.7% vs. 25%). Pleural effusion was present in only one patient with LHS [67]. The classic triad was present in 74.5% vs. 93.8% of patients.

### Autoantibody Testing and Type of Autoantibodies

Evaluation for at least one autoantibody was performed in 58/63 (92.1%) patients in the entire cohort. The completeness of antibody testing varied widely. Evaluation for CD-specific antibodies was performed in 22/63 (34.9%) patients. Seventeen out of 63 (26.9%) patients tested positive for an autoantibody. Thirteen out of 17 (76.4%) of patients tested positive for anti-CD antibodies. The prevalence of CD antibodies among tested patients was 13/22 (59%). The details of these patients with LHS are provided in Tables 2-3.

| Author               | Gender | Age at IPH diagnosis (year) | County | Presenting symptoms | Duration of presenting symptoms | Age at respiratory symptom onset (year) | Delay in IPH diagnosis | Autoantibody tested | Positive antibody | Temporal relation with initial diagnosis | Prominent GI symptoms | Other organ involvement |
|----------------------|--------|-----------------------------|--------|---------------------|---------------------------------|----------------------------------------|------------------------|---------------------|-------------------|----------------------------------------|-----------------------|-----------------------|
| Austin et al. 2021   | M      | 39                          | NS/USA | Hemoptysis, dyspnea  | 2 days                          | 20                                    | 1 year                  | ANA, ANCA, anti-GBM | Anti-TTG     | CD diagnosed 5 years before IPH but patient had hemoptysis 5 years before the diagnosis of CD | Minimal Workup for CD Aneurysm for chronic anemia | Membranous nephropathy |
| Korda et al. 2016    | M      | 21                          | NS/Turkey | Hemoptysis, dyspnea | 2 days                          | 21                                    | None                   | ANA, ANCA, anti-GBM | Anti-TTG     | At the time of IPH diagnosis              | No                    | None                  |
| Popp et al. 2016     | F      | 48                          | NS/Romania | Recent hemoptysis with severe acute hemoptysis | NA                              | NA                                    | NA                     | ANA, ANCA, anti-GBM | Anti-gludin antibody | At the time of IPH diagnosis              | No                    | None                  |
| Berger et al. 2015   | F      | 26                          | NS/USA | Cough, hemoptysis, exertional shortness of breath, and fatigue | Cough and hemoptysis for 6 months. Fatigue and SOB for 2 months | 26                                    | None                   | ANA, ANCA, anti-GBM | Anti-gludin antibody | At the time of IPH diagnosis              | No                    | None                  |
| Khairani et al. 2015 | M      | 19                          | NS/India | Hemoptysis, dyspnea, and fatigue | 2 years                         | 16                                    | 3 years                | ANA, ANCA, RF, anti-cardiolipin, anti-GBM | Anti-TTG antibody | At the time of IPH diagnosis              | No                    | Dilated cardiomypathy, EF 25%            |
| Doss Santos et al. 2013 | M    | 29                          | White/Brazil | Cough, shortness of breath, weight loss | 5 months                        | 29                                    | None                   | ANA, ANCA, P-ANCA, C-ANCA, anti-GBM | Anti-gludin antibody | At the time of IPH diagnosis              | No                    | None                  |
| Pietrucco et al. 2012 | M    | 27                          | NS/Italy | Recurrent hemoptysis at age 27. Worsening dyspnea at 31 | Admission to the hospital with anemia, dyspnea, and hemoptysis at age 31 | 27                                    | None                   | Negative IgA, anti-TTG and anti-endomysial antibody at age 27 | Positive anti-gludin, endomydal, and TgG antibody at age 31 | 4 years after diagnosis of IPH | No                    | Mysocardin, atrial and ventricular tachyarrhythmia at age 26. Dilated cardiomypathy (EF 24%) at age 31. EF 57% at age 35 |
TABLE 2: The reported 16 adult cases diagnosed as idiopathic pulmonary hemosiderosis (IPH) having a workup for autoantibodies, including evidence of celiac disease (Lane-Hamilton syndrome)

| Author               | Modality of IPH diagnosis | Chest radiology | Bronchoscopy/Gastric aspiration findings | Lung histopathology | Small intestinal histopathology | Serum ferritin | Initial treatment | Recurrence of IPH | Clinical course of CD | Follow-up (years) | Respiratory outcomes |
|----------------------|---------------------------|-----------------|----------------------------------------|---------------------|---------------------------------|----------------|------------------|---------------------|---------------------|---------------------|-----------------------|
| Singh et al. 2013    |                           |                 | Hemoptysis with up to 400 ml of fresh blood | 2 months            | 27                              | None           | None             | At the time of IPH diagnosis | No                  | None                |
| Naik et al. 2016     |                           |                 | Hemoptysis, shortness of breath, dyspnea, and orthostasis |                    | ANA, P-ANCA, C-ANCA, anti-GBM, and anti-dsDNA; negative | ANA 1:160 Anti-TTG and endomysial antibody | Patient had a history of CD; diagnosed 10 years ago | Not at the time of DAH | None                |
| Mayes et al. 2008    |                           |                 | Hemoptysis and shortness of breath | 3 months            | 40                              | None           | Anti-ANA, ANCA, P-ANCA, C-ANCA, anti-GBM, and anti-dsDNA; negative | At the time of IPH diagnosis | No                  | None                |
| Jecko et al. 2007    |                           |                 | Hemoptysis, chest pain, fever | 3 years            | 17                              | None           | ANA, anti-GBM negative | None | Diagnosed with CD 12 years ago | NS                  | None                |
| Mahora et al. 2006   |                           |                 | Hemoptysis, worsening dyspnea | 5 days              | 24                              | 4 years         | Anti-IgA endomysial antibody | At the time of IPH diagnosis | No                  | None                |
| Roux et al. 1984     |                           |                 | Recurrent hemoptysis | More than a year | 18                              | 1 year          | ANA, anti-GBM, RF, anti-Scl-70, and anti-dsDNA; negative | Anti-reticulin and gliadin antibodies | At the time of IPH diagnosis | No                  | None                |
| Pacheco et al. 1991  |                           |                 | Hemoptysis, exertional shortness of breath, and arthralgia | 15 years            | 7                               | 15 years        | ANA, anti-GBM, RF negative | Anti-reticulin antibody 1:640 | At the time of diagnosis of IPH | No                  | None                |
| Ludmaler et al. 1986 |                           |                 | Recurrent pulmonary cough and hemoptysis | 2 months            | 36                              | None           | ANA, RF negative | NA | 2 months after IPH diagnosis | Yes                  | None                |
| Lane et al. 1971     |                           |                 | Hemoptysis at age 18 | NS                  | NS                              | None           | RF negative | NA | At the time of IPH diagnosis | Yes, since age 9 | None                |

AN A, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; c-ANCA, cytoplasmic ANCA; CD, celiac disease; dsDNA, double-stranded DNA; EF, ejection fraction; GBM, glomerular basement membrane; IPH, idiopathic pulmonary hemosiderosis; P-ANCA, perinuclear ANCA; RF, rheumatoid factor; RNP, ribonucleoprotein; TTG, tissue transglutaminase
| Author et al. | Year | Technique | Pathology | Diagnosis | Follow-up |铁 | Iron | NS | NS | NS |
|--------------|------|----------|-----------|-----------|-----------|---|---|---|---|---|
| Austin et al. | 2022 | VATS | Infiltaration, mediasinal adenopathy, right lower lobe consolidation; and right-sided pleural effusion | Intraalveolar HLM, type 2 pneumocyte hyperplasia | Biopsy compatible to CD but not specified | Elevated | None | NS | Yes, NS if there was recurrence with CS and GFD | NS | NS | NS |
| Kestrel et al. | 2016 | BAL | Mildly hemorrhagic fluid on BAL, hemorrhid-laden macrophages | Not performed | Durvalian biopsy: Intraluminal plasma cells and eosinophils, Villous atrophy, and cyst hyperplasia | Low normal | None | Hemoglobin normalized | 0.87 years | Completely normal |
| Poppe et al. | 2016 | BAL | Diffuse pulmonary interstitial emphysema suggestive of alveolar hemorrhage | No malignancy, muco; rare RBE, and HLM on BAL | Nodular perivascular buds. Durvalian biopsy: Villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes | NS | GFD and tapering steroids | None | Hemoglobin normalized | 3.5 years | Clinical and radiologic improvement |
| Berger et al. | 2015 | BAL and transbronchial biopsy | Bilateral GGO | Normal bronchial mucosa | Conglomeration of HLM in the alveoli and thickening of alveolar interstitium, no vascular or inflammatory infiltrate | NS | CS and GFD was tapered after 9 months of therapy | None | Normal respiratory function and normal hemoglobin | 4 years | Normal respiratory function, mild subpleural residual thins |
| Khansuri et al. | 2015 | BAL and transbronchial biopsy | Bilateral GGO | NS | Type 2 pneumocyte hyperplasia, HLM in the alveolar space, and chronic inflammatory cells | Normal | CS and GFD | None | Improved hemoglobin | 2 years | Relamination of hemoglobin, impaired PFT, 67% improved to 30% |
| Dias Santos et al. | 2012 | BAL | Bilateral GGO and consolidation | HLM from BAL | Not performed | Durvalian biopsy: Villous flattening, intraepithelial lymphocyte | NS | Iron deficiency anemia | GFD | Normalization of hemoglobin | 0.5 years | Completely normal respiratory function |
| Patuca et al. | 2012 | BAL and transbronchial biopsy at age 29 | Bilateral subepithelial infiltrate | NS | HLM in the alveoli without any evidence of vasculitis | Normal | CS with tapering dose at age 27 | None | Normalization of hemoglobin | 4 years | Normalization of PFT |
| Singhal et al. | 2012 | BAL | Bilateral diffuse alveolar infiltrate in the mid and lower lung zone | Numerous HLM | Durvalian biopsy: Peribulillary atrophy, increased intraepithelial lymphocyte and plasma cells in lamina propria | NS | Iron deficiency anemia | GFD | Normalization of hemoglobin, weight gain | 1 year | Complete normal pulmonary function |
| Nottebohm et al. | 2012 | Bronchoscopy and lung biopsy | Bilateral GGO (more prominent in LUL and right upper and middle lobes) | NS Bronchoscopy consistent with CD | Intraalveolar HLM | NS (patient was diagnosed with CD 10 years ago) | NS | Iron deficiency anemia | NS | NS | NS | NS | NS | NS |
TABLE 3: Treatment and outcomes of the 16 adult cases with IPH and celiac disease (Lane-Hamilton syndrome)

| Study Ref. | Bronchoscopy and/or Biopsy | Lung Biopsy | Small Bowel Biopsy | Other Biopsy | Treatment | Clinical Improvement | Pulmonary Function |
|------------|-----------------------------|-------------|--------------------|--------------|------------|---------------------|-------------------|
| Mayes et al. 2008 [41] | Bronchoscopy and VATS lung biopsy | Bilateral lower lobes, interstitial opacity in upper lobes | Bronchoscopy not diagnostic | N/A | GFD | NS | NS | No more hemoptysis |
| Jacob et al. 2007 [37] | BAL | Diffuse bilateral infiltrate | HLM from BAL | Not performed | N/A | N/A | NS | Ongoing anemia |
| Mehra et al. 2004 [39] | BAL and transbronchial biopsy | Diffuse GGO in bilateral mid and lower lung zones | Hemorrhagic fluid with >80% HLM | Not performed | N/A | N/A | NS | Improved hemoglobin and reduced antibody titer |
| Brouns et al. 1994 [77] | BAL and transbronchial biopsy | Diffuse bilateral alveolar infiltrate primarily in the lower lobes | Progressive bloody return on BAL-HLM | N/A | N/A | NS | NS | Persisted clinical improvement |
| Pacheco et al. 1991 [26] | BAL and transbronchial lung biopsy | Bilateral micronodular opacity | Eosinophil infiltration on BAL-HLM | N/A | N/A | NS | NS | No recurrence of hemoptysis |
| Ludmiller et al. 1985 [22] | Lung biopsy | NA | NA | N/A | Azathioprine | Yes | NS | Stabilization of pulmonary function |
| Lane et al. 1971 [11] | Sputum and lung biopsy | Bilateral patchy infiltrates in lower lobes | Iron laden macrophages in sputum | Lung biopsy consistent with IPH | N/A | NS | Persistent GI symptoms | Ongoing small volume hemoptysis |

**Notes:**
- BAL, bronchoalveolar lavage; CD, celiac disease; EF, ejection fraction; EM, electron microscopy; GFD, gluten-free diet; GGO, ground-glass opacity; GI, gastrointestinal; HLM, hemosiderin-laden macrophages; IPH, idiopathic pulmonary hemosiderosis; LLL, left lower lobe; NS, not specified; PFT, pulmonary function tests; VATS, video-assisted thoracoscopic surgery.
Diagnosis of CD and Associated Autoantibodies

The prevalence of CD in patients with IPH in the predefined period was 16/64 (25%). All but one study specified histopathologic analysis of small bowel biopsy to confirm CD [45]. Three out of 16 patients were known to have CD before the diagnosis of IPH [37,45,67]. Two patients were diagnosed with CD after IPH was identified [22,52]. In the remaining 11 patients, the diagnosis of IPH and CD were made simultaneously. Ten of these 11 patients initially tested positive for anti-CD antibody, followed by a biopsy. Only two of 15 (13.3%) patients reported any noticeable gastrointestinal symptoms. Workup for CD was performed either because of the known association with IPH or to evaluate for disproportionate anemia.

Regarding specific anti-CD antibodies, the positivity was as follows: TTG, 7/12, endomysial antibody 6/8, anti-gliadin antibody 6/10, and anti-reticulin antibody 2/2. Three studies did not report any serologic workup for CD, and the diagnosis was made by small bowel biopsy [11,22,37].

Diagnosis of IPH

A definitive diagnosis of IPH was made by lung biopsy in 41/49 (83.7%) patients in cohort A and 11/16 (68.8%) patients in cohort B. The biopsy techniques employed between cohorts A and B are as follows: surgical lung biopsy (46.3% vs. 27.2%), video-assisted thoracoscopic surgery (21.95% vs. 18.18%), and transbronchial lung biopsy (TBLB; 24.39% vs. 34.54%). One of the TBLB was a cryobiopsy [67]. In cohort A, the histopathologic analysis was performed post-mortem in three (7.5%). Eight of eight patients in cohort A who did not have lung histopathology, five were diagnosed by the demonstration of HLM from bronchoalveolar lavage (BAL), three by a progressively bloody return from BAL, and one by HLM in sputum. All five patients in cohort B without lung biopsy were diagnosed by HLM from BAL.

Treatment

Following the diagnosis of IPH, immunosuppressive medications were used in 37/46 (80.4%) patients in cohort A and 11/16 (68.8%) patients in cohort B. Corticosteroid (CS) was the most popular first-line medication in 35/37 (94.6%). The other two patients were started on azathioprine (AZA) as first line therapy [17,20]. Ten out of 35 (28.6%) patients who initially received CS required a second-line medication. Seven out of 10 received AZA, 2/10 were given antimalarials, and one patient was treated with cyclophosphamide (CYC). In contrast, only 6/15 (40%) of patients in cohort B received immunosuppression. Five of these patients received CS, and one was treated with AZA. All patients except one were treated with GFD [11]. The treatment for CD was unknown at the time of the original report by Drs. Lane and Hamilton [11]. As a result, this patient received therapy with AZA. The treatment was not specified in one patient [45]. Nine out of 15 (60%) patients were discharged only on GFD without corticosteroid (CS) therapy [22,26-27,31,37,41,55,58,72]. Only one of these patients subsequently required CS due to declining pulmonary function tests [41]. Three patients were initially treated with GFD and CS, and successfully tapered off steroids [52,55,59]. One patient, in addition to GFD, required long-term CS [67]. However, the compliance to GFD in this patient was questionable.

Clinical Course and Follow-Up

The median follow-up period in cohorts A and B were 1.4 (IQR, 3.21) vs. 0.75 (IQR, 2) years, respectively (non-normally distributed data). The mean difference between the cohorts was not statistically significant (p=.149). Recurrence during follow-up was reported in 56.8% (21/37) of patients in cohort A and 28.6% (4/14) of patients in cohort B (chi-square test, p=.086). Two of these patients were not on a gluten-free diet (GFD) at the time of recurrence [11,52]. The other two patients still had IPH symptoms despite being on GFD [41,67]. Ten out of 47 (21.3%) patients died in cohort A, but all patients were alive at the time of the follow-up in cohort B (Fisher’s exact test, p=.098).

Discussion

Since first described in 1971 by Drs. Lane and Hamilton [11], multiple papers have been published reporting the coexistence of IPH and CD in adult patients. However, a comparative analysis between patients with IPH and LHS has never been done to the best of our knowledge. Therefore, we have performed a systematic review of adult patients with IPH with or without concomitant CD in the past 50 years and reported the similarities and differences between these two groups of patients.

Our study reaffirmed the previous notion that IPH is more common among males in the adult population, but unlike the study by Chen et al. [73], most of our patients (in both cohorts) were diagnosed before the age of 30 years. The patients with LHS are younger at symptom onset (statistically significant) and at the time of diagnosis of IPH compared to patients without CD, findings that had not been reported before.

CD or gluten-sensitive enteropathy is a common autoimmune disease with an adult population prevalence of approximately 1% [74]. CD is more prevalent in the pediatric population and in women than men [74].
Although LHS has been a known entity for half a century, the prevalence of LHS among IPH patients has been unknown. In children with IPH, the prevalence of anti-CD antibodies was 25.9% [13]. Based on this review, the prevalence among adults is also 25%. However, when only patients who had been specifically evaluated for CD by serologic testing are considered, the prevalence is as high as 59%. The fact that the prevalence is so high in children and adults, and the number is significantly higher than the general population, raises concerns for unifying the underlying pathobiology of this co-occurrence. Several hypothetical mechanisms of DAH in CD have been considered, such as food allergen-induced immune-complex deposition, anti-reticulin antibody-mediated alveolar basement membrane damage, and molecular mimicry of an infectious pathogen [75-77]. However, there has never been any histopathologic proof to support any of them.

The pathobiology of DAH in IPH is currently unknown. Genetic, environmental, and allergic hypotheses have been proposed but do not appear to be of much merit [1]. The immunologic hypothesis is the most popular among clinicians. We have proposed a new pathogenetic hypothesis for the occurrence of DAH in IPH [78]. We believe that the etiology of DAH is cytokines and chemokines, such as histamine, eosinophilic cationic protein, and vascular endothelial growth factor-induced changes in pulmonary capillaries that promote increased gap between endothelial cells leading to RBC extravasation in the alveolar space without any structural vascular damage. The cytokines are expressed by the immunologic cells, such as eosinophils, basophils, and lymphocytes, when exposure to an unknown antigen occurs locally in the lung or through another route such as enterally. Moreover, an overall immune dysregulation in IPH could explain the susceptibility among these individuals to develop autoantibodies and other immune-mediated diseases [16,79-83]. We have proposed a new name, immune-mediated pulmonary hemosiderosis (ImPH), to focus on the immunologic causation of DAH [84-85].

The presenting symptoms in IPH are nonspecific. Patients generally present with hemoptysis of variable severity ranging from intermittent episodes of blood-streaked sputum to life-threatening pulmonary hemorrhage [58,64]. Other symptoms include cough with or without sputum production, dyspnea, and chest pain. Although hemoptysis is common in adult patients, pediatric patients may not have hemoptysis due to inadvertent swallowing of the sputum. Systemic symptoms affect approximately half of the patients [56]. The classic triad consists of hemoptysis, radiologic chest abnormalities, and anemia. Anemia appears to be more prevalent in LHS patients than patients without CD. All patients with LHS in our study suffered from anemia. This could be due to chronic malabsorption and resultant iron deficiency in addition to chronic alveolar hemorrhage. The most common radiologic findings during the acute phase of the disease include bilateral ground-glass opacities on chest computed tomography [87]. In addition, areas of consolidation may also be present [3]. Typically, the mid and lower lung zones are affected more than the upper zones, but this is not universal [1]. Other less common radiologic changes, such as emphysema, cystic changes, and interstitial infiltrate, were seen in similar frequencies between IPH and LHS patients [58]. The median delay in the diagnosis from symptom onset was one year and similar between both groups.

Although IPH is considered an immunologic disease [84], unlike other autoimmune diseases, multisystem involvement by IPH has never been definitively proven. There are reports of myocardial dysfunction [89], myocarditis [14], conduction system [90] and segmental wall motion abnormalities [15], and sudden death [91] in patients with IPH, but histopathologic analysis of myocardial tissue has not demonstrated hemosiderin deposition as the underlying etiology [14,89-90]. We have identified two patients in cohort B who also suffered from dilated cardiomyopathy [52,56]. Previous studies have demonstrated a higher prevalence of anti-CD antibodies in patients with autoimmune myocarditis [92-93]. Whether IPH, CD, and autoimmune myocarditis stem from the same immunologic process is unknown at this time. Genome-wide association studies may shed more light on this association. One patient in cohort B also suffered from membranous nephropathy [67].

One of the crucial and interesting findings in this study was the lack of GI symptoms in patients with LHS [26-27,31,37,41,45,52-53,55,56,58-59,67,72]. Less than 20% of patients complained of any significant GI symptoms at the time of IPH diagnosis. Similar findings were also seen in pediatric patients with LHS [77]. Although malabsorption leading to developmental delay is common in children with LHS, this is rarely the case in adults [53]. As a result, reliance on clinical symptoms only may underestimate the possibility of CD in IPH patients, and patients should undergo workup for CD. The workup for CD often starts with serologic assays for anti-CD antibodies. These antibodies are very sensitive and specific for CD. The commonly tested antibodies are anti-tissue transglutaminase (anti-TTG) and anti-endomysial IgA antibodies [94]. In patients with selective IgA deficiency, IgG antibodies against these antigens could be tested. Other autoantibodies, such as anti-gliadin and anti-reticulin antibodies, have fallen out of favor. Positive antibody testing is generally followed by a small intestinal biopsy for histopathologic proof of CD. The typical histopathologic findings in CD are intraepithelial lymphocytosis, infiltration of the lamina propria by plasma cells, neutrophils and eosinophils, crypt hyperplasia, and variable degrees of villous blunting [95]. To standardize histopathologic reporting, pathologists often use a modified Marsh classification. According to this classification, the severity of small bowel involvement ranges from stage I to stage IIC, where stage I represents the earliest changes characterized by only increased intraepithelial lymphocyte count (>40 cells/100 enterocytes), and stage IIC demonstrates total villous atrophy and crypt hyperplasia in addition to IEL [96]. The histopathologic terminologies varied among authors in the included manuscripts, likely due to regional differences in reporting practice.
The definitive diagnosis of IPH requires histopathologic analysis of the lung parenchyma. However, this practice does not appear to be universal, and identification of HLM from BAL or even sputum has been considered adequate by authors in the previous reports [21]. As HLM can be present from BAL even without DAH (bleeding from the airways will accumulate in the alveolus and subsequently HLM can be present after 48-72 hours), it is important to make a diagnosis of DAH by demonstrating progressively bloody fluid return on serial BAL [2,97]. Transbronchial biopsies can be easily performed during bronchoscopy, but the samples are of small size. Transbronchial cryobiopsy provides larger and better-preserved samples with a higher risk of bleeding complications [65,98]. The surgical lung biopsy, either by thoracotomy or video-assisted thoracoscopic surgery (VATS), was performed in 68% of patients in the IPH and 45% of the LHS cohort. It is possible that due to the previously known association between CD and IPH, clinicians were more comfortable making a diagnosis of IPH from BAL and transbronchial biopsy (TBB) without obtaining a surgical lung biopsy, which is more invasive.

Systemic CS represents the first-line therapy during active disease as well as for maintenance therapy [99]. Approximately one-third of reported adult patients have required a second-line immunosuppressive agent to control their disease [86]. Unconventional therapies, such as liposteroid, leflunomide, and mesenchymal stem cell transplant, have also been tried [100-102]. In contrast, GFD alone was effective in controlling DAH in the majority of patients with LHS. Only one patient in the literature required additional immunosuppressive therapy for DAH while following GFD. Patients who were simultaneously started on CS and GFD were able to come off of all immunosuppressive therapy within a short period of time. Therefore, unless the patient suffers from life-threatening alveolar hemorrhage, most patients can be started on CS prior to initiation of corticosteroid (CS). If CS is started, care should be taken to rapidly taper off and discontinue such therapy as it is associated with a significant side-effect profile.

Even during the short follow-up period, recurrence was common among the entire cohort. A trend towards less recurrence was noted in the LHS cohort, especially when the patient was compliant with GFD. Similarly, survival was also better in that cohort. No patient with LHS died during the follow-up. These findings have raised the possibility of whether IPH in adults has different endotypes and phenotypes. Patients with LHS may have a milder form of the disease with less recurrence risk and better survival compared to IPH patients without CD. If that were true, evaluation for CD is crucial as the treatment intensity with immunosuppressive therapy can be modified based on the presence or absence of CD. As two patients in our study developed CD antibodies after the diagnosis of IPH, and it may be prudent to intermittently check for them during follow-up [22,52].

**Strength and limitations of the study**

Our study has several limitations. First, the number of patients with LHS is modest, likely due to the rarity of the disease. Second, most patients have been reported as ‘case reports’ and therefore may not have included all pertinent parameters. Third, we excluded literature published in a non-English language, which may have reduced the number of cases. Fourth, the follow-up period was limited, and the true prognosis may not have been clearly evident fifth, there was a risk of bias in the reporting, as only selected cases with particularly positive or negative outcomes may have been reported. Despite that, this study adds significantly to the existing literature on adult IPH. The similarities and discrepancies between IPH and LHS regarding patient demographics, clinical presentation, treatment, and prognosis have never been studied before.

**Conclusions**

IPH is a rare disease of unknown etiology and pathogenesis. In this manuscript, we have reported the similarities and differences between adult patients with IPH and LHS. From our review of the literature, we have identified a high prevalence of CD among adult patients with IPH. Patients with LHS are younger and start experiencing respiratory symptoms earlier than adult IPH patients. The classic triad is more common in LHS, but the delay in diagnosis between both groups is similar. Fewer patients with LHS undergo lung biopsy for a diagnosis of IPH than patients without CD. GFD is often the first line of treatment and appears to be efficacious. Some patients require additional immunosuppressants and, more often than not, are able to come off it. The risk of recurrence is likely lower, and the chance of survival is higher among patients with LHS than IPH patients. A new diagnosis of IPH in adults should prompt serologic evaluation for CD.

**Additional Information**

**Disclosures**

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors declare that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
References

1. Saha BK: Idiopathic pulmonary hemosiderosis: a state of the art review. Respir Med. 2021, 176:106234. 10.1016/j.resmed.2020.106234
2. Ioachimescu OC, Sieber S, Kotch A: Idiopathic pulmonary haemosiderosis revisited. Eur Respir J. 2004, 24:162-70. 10.1183/09031936.04.01163502
3. Saha BK, Chong WH: Diffuse alveolar hemorrhage in cardiac diseases. Lung. 2021, 199:105-12. 10.1007/s00134-021-00853-x
4. Saha S, Chong WH, Saha BK: Unilateral diffuse alveolar hemorrhage due to selective directionality of mitral regurgitant jet in a patient with severe aortic stenosis. Cureus. 2021, 13:e14714. 10.7759/cureus.14714
5. Corrin B, Jagusch M, Dewar A, et al.: Fine structural changes in idiopathic pulmonary haemosiderosis. J Pathol. 1987, 153:249-56. 10.1002/path.1711530309
6. Aiman A, Saha S, Chong WH, Saha BK: A 49-year-old man with ischemic cardiomyopathy and persistent hemothysis for eighteen months [In Press]. Am J Med Sci. 2022. 10.1097/ajms.2021.10.030
7. Castranova V, Bowman L, Miles PR, Reaor MJ: Toxicity of metal ions to alveolar macrophages. Am J Ind Med. 1980, 1:549-57. 10.1002/ajim.4700010311
8. Egan JJ, Martin N, Hasleton PS, et al.: Pulmonary interstitial fibrosis and haemosiderin-laden macrophages: late following heart transplantation. Respir Med. 1996, 90:547-51. 10.1016/0002-9343(96)90147-x
9. Zakynthinos E, Vassilakopoulos T, Kultasa P, Malagari E, Daniil Z, Roussoucs E, Zakynthinos SG: Pulmonary hypertension, interstitial lung fibrosis, and lung iron deposition in thalassaemia major. Thorax. 2001, 56:737-9. 10.1136/thorax.56.9.737
10. Saha BK, Chong WH: Lung transplant to manage end-stage lung disease due to idiopathic pulmonary hemosiderosis: a review of the literature. Respir Invest. 2022, 60:82-9. 10.1016/j.respi.2021.06.009
11. Lane DJ, Hamilton WS: Idiopathic steatorrhoea and idiopathic pulmonary haemosiderosis. Br Med J. 1971, 2:890-9. 10.1136/bmj.2.5753.889
12. Page MJ, McKenzie JE, Bossuyt PM, et al.: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021, 10.1361/s13636-021-01626-4
13. Saha BK, Bonnier A, Chenna P, Milman NT: Prevalence of autoantibodies in pediatric patients with idiopathic pulmonary hemosiderosis: a scoping review of the literature in the period 1980-2021. Clin Rheumatol. 2022, 41:977-90. 10.1007/s10067-021-06029-3
14. Jiji V, Hofkin GA: Idiopathic pulmonary hemosiderosis. South Med J. 1974, 67:488-91. 10.1097/00007611-197404000-00025
15. Bavy AA, Krooper S, Alpert IS: Segmental wall motion abnormalities in an individual with idiopathic pulmonary hemosiderosis. Cardiology. 2000, 95:201-4. 10.1159/000007027
16. Fujii M, Miyahara N, Tanimoto Y, et al.: Diffuse alveolar hemorrhage with chronic thyroiditis in an advanced-age adult. Respir Med CME. 2010, 5:90-2. 10.1016/j.rmed.2009.04.006
17. Byrd RB, Trunk G: Systemic lupus erythematosus presenting as pulmonary hemosiderosis. Chest. 1973, 64:128-9. 10.1378/chest.64.1.128
18. Irwin RS, Cottrell TS, Hsu KC, Griswold WR, Thomas HM 3rd: Idiopathic pulmonary hemosiderosis: an electron microscopic and immunofluorescent study. Chest. 1974, 65:41-5. 10.1378/chest.65.1.41
19. Dolan CJ Jr, Sodes CH, Duffy FD: Idiopathic pulmonary hemosiderosis. Electron microscopic, immunofluorescent, and iron kinetic studies. Chest. 1975, 68:577-80. 10.1378/chest.68.4.577
20. Pozo-Rodríguez F, Freire-Campo JM, Gutierrez-Millet V, Barbosa-Ayúcar C, Díaz de Atauri J, Martín-Escribano P: Idiopathic pulmonary hemosiderosis treated by plasmapheresis. Thorax. 1980, 35:599-400. 10.1136/thrx.35.5.399
21. Moses HW, Schreiner BF Jr, Hyde RW, Kallay MC: Heart block and idiopathic pulmonary hemosiderosis. Pacific Clin Electrophysiol. 1982, 5:826-8. 10.1111/j.1540-8159.1982.tb06565.x
22. Hemoptysis, pulmonary infiltrates, and diarrhea in a 36-year-old man. Am J Med. 1986, 80:950-8. 10.1016/0002-9345(86)90406-6
23. Nomura S, Kanoh T: Association of idiopathic pulmonary haemosiderosis with IgA monoclonal gammopathy. Thorax. 1987, 42:696-7. 10.1136/thx.42.9.696
24. Bain SC, Bryan RL, Hawkins JB: Idiopathic pulmonary haemosiderosis and autoimmune thryotoxicosis. Respir Med. 1989, 83:447-50. 10.1016/s0954-6111(89)80082-4
25. Chauhuyu AA, Dobson CM, Simpson FG: Pulmonary hemosiderosis associated with left atrial myxoma. Thorax. 1991, 46:539-40. 10.1136/thrx.46.7.539
26. Pacheco A, Casanova C, Foge L, Suero A: Long-term clinical follow-up of adult idiopathic pulmonary hemosiderosis and celiac disease. Chest. 1991, 99:1525-6. 10.1378/chest.99.6.1525
27. Bourns D, Panagou P, Rokkas T, Sfakas N: Bronchoalveolar lavage findings in a young adult with idiopathic pulmonary hemosiderosis and coeliac disease. Eur Respir J. 1994, 7:1009-12.
28. Godyo I, Leite RM, Yoo HH, Defavari J, Càteuño A, Quezás TH. Idiopathic pulmonary hemosiderosis with epidermoid lesions: a rare presentation. Am J Med Sci. 2000, 319:411-5. 10.1097/00000441-200006000-00012
29. Tedeschi A, Loriini M, Giannini S, Ciceri L, Suli C, Airaghi L: Serum histamine-releasing activity in a patient with idiopathic pulmonary hemosiderosis. Allergol Immunopathol. 2001, 29:281-3. 10.1016/s0002-9406(01)07907-2
30. Helman DL, Sullivan A, Kariya ST, Deering SH, Huepchen NA, Shorr AF: Management of idiopathic pulmonary haemosiderosis in pregnancy: report of two cases. Respiropathy. 2005, 8:398-400. 10.1046/j.1440-1842.2005.00477.x
31. Malhotra P, Aggarwal R, Aggarwal AN, Jindal SK, Awasthi A, Radotra BD: Coeliac disease as a cause of unusually severe anaemia in a young man with idiopathic pulmonary haemosiderosis. Respir Med. 2005, 99:451-3. 10.1016/j.rmed.2004.09.007
32. Turay UY, Ergün P, Erdögun Y, Biber C, Demiriz F, Kreyf IA: Idiopathic pulmonary haemosiderosis. Tuberk ve Toraks. 2004, 52:582-5.
33. Soto RG, Soares MM: Idiopathic pulmonary hemosiderosis in pregnancy: anesthetic implications. J Clin Anesth. 2005, 17:482-4. 10.1016/j.jclinane.2005.06.002
A 74-year-old male with intermittent hemoptysis

a few good men: A Marine with hemoptysis and diarrhea. Idiopathic pulmonary hemosiderosis and celiac sprue. Chest. 2008, 134:644-7. 10.1378/chest.07-2834

A case report. J Bras Patol E Med Lab. 2013, 49:216-21. 10.1590/S1726-49012013000300010

A 74-year-old male with intermittent hemoptysis. https://static.diseaseinfo.iupui.edu/divisions/pulmonary/content/Dukiewicz.pdf

A few good men: A Marine with hemoptysis and diarrhea. Idiopathic pulmonary hemosiderosis and celiac sprue. Chest. 2008, 134:644-7. 10.1378/chest.07-2834

Idiopathic pulmonary hemosiderosis with celiac disease (Lane-Hamilton syndrome) in an adult - a case report. Monaldi Arch Chest Dis. 2020, 90:10.4081/monaldi.2020.1267

A few good men: A Marine with hemoptysis and diarrhea. Idiopathic pulmonary hemosiderosis and celiac sprue. Chest. 2008, 134:644-7. 10.1378/chest.07-2834

A rare cause of chronic anemia. Monaldi Arch Chest Dis. 2020, 90:10.4081/monaldi.2020.1267

A 74-year-old male with intermittent hemoptysis.
100
99
98
97
96
95
94
93
92
91
90
89
88
87
86
85
84
83
82
81
80
79
78
77
76
75
74
73
72
71
70
69
68
67
66
65
64
63
62
61
60
59
58
57
56
55
54
53
52
51
50
49
48
47
46
45
44
43
42
41
40
39
38
37
36
35
34
33
32
31
30
29
28
27
26
25
24
23
22
21
20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1

Saha BK, Milman NT: Alveolar capillary basement membrane lesions in Goodpasture’s syndrome and idiopathic pulmonary hemosiderosis. Am J Med. 1975, 59:642-9. 10.1016/0002-9345(75)90225-9

Santos JW, Mello Neto AB, Marchiori RC, Michel GT, Fagundes AL, Tagliari LG, Cancian T: Pulmonary hemosiderosis associated with celiac disease: improvement after a gluten-free diet. J Bras Pneumol. 2012, 38:412-4. 10.1590/s1806-37152012000500020

Chen XY, Sun JM, Huang XJ: Idiopathic pulmonary hemosiderosis in adults: review of cases reported in the latest 15 years. Clin Respir J. 2017, 11:677-81. 10.1111/crj.12440

Singh P, Arora A, Strand TA, et al.: Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018, 16:823-836.e2. 10.1016/j.cgh.2017.06.057

Plot L, Amital H: Infectious associations of Celiac disease. Autoimmun Rev. 2009, 8:516-9. 10.1016/j.autrev.2008.10.001

Hendricks GF, Somers K, Vandenburg L: Lane-Hamilton syndrome: case report and review of the literature. Eur J Pediatr. 2011, 170:1597-602. 10.1007/s00431-011-1568-5

Saha BK, Saha S, Bonnier A, Saha BN: Association between idiopathic pulmonary hemosiderosis and celiac disease in pediatric patients: a scoping review of the literature over the past 50 years. Pediatr Pulmonol. 2022, [Epub ahead of print]:10.1002/ppul.25847

Saha BK, Chong WH, Saha S, Aiman A, Bonnier A: Proposed pathogenesis of diffuse alveolar hemorrhage in idiopathic pulmonary hemosiderosis. Lung. 2022, [Epub ahead of print]:10.1007/s00408-022-00525-4

Stainer A, Rice A, Devaraj A, et al.: Diffuse alveolar hemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults. BMC Pulm Med. 2019, 19:185. 10.1186/s12890-019-0947-y

Freitas A, Senra V, Marinho A, Guedes M: Chronic alveolar hemorrhage in a paediatric patient: a diagnostic and treatment challenge. BMJ Case Rep. 2015, 2015:bcr2014206656. 10.1136/bcr-2014-206656

Yaonagihara T, Yamamoto Y, Hamada N, et al.: Recurrent idiopathic pulmonary hemosiderosis after long-term remission presented with Sjogren’s syndrome: idiopathic no more?. Respir Med Case Rep. 2018, 25:68-72. 10.1016/j.rmcr.2018.06.013

Taytard J, Nathan N, de Blic J, et al.: New insights into pediatric idiopathic pulmonary hemosiderosis: the French RespilRare® cohort. Orphanet J Rare Dis. 2015, 18:81.161. 10.1007/s13023-018-0806-6

Alimi A, Taytard J, Abou Taam R, et al.: Pulmonary hemosiderosis in children with Down syndrome: a national experience. Orphanet J Rare Dis. 2018, 15:30. 10.1007/s13023-018-0806-6

Saha BK, Chong WH, Milman NT: Differentiation of idiopathic pulmonary hemosiderosis from rheumatologic and autoimmune diseases causing diffuse alveolar hemorrhage: establishing a diagnostic approach. Clin Rheumatol. 2022, 41:325-56. 10.1007/s10067-021-05959-1

Saha BK: Is it time to call idiopathic pulmonary hemorrhosis by the correct name: immune-mediated pulmonary hemosiderosis?. Am J Med Sci. 2021, 361:809-11. 10.1097/AMJ.0000000000002158

Saha BK, Bonnier A, Saha S, Saha BN, Shkolnik B: Adult patients with idiopathic pulmonary hemosiderosis: a comprehensive review of the literature. Clin Rheumatol. 2022, [Epub ahead of print]:10.1007/s10067-022-06104-3

Cheal FK, Sheppard MN, Hansell DM: Computed tomography of diffuse pulmonary hemorrhage with pathological correlation. Clin Radiol. 1993, 48:89-95. 10.1016/0300-6000(93)90102-5

Khorashadi L, Wu CC, Betancourt SL, Carter BW: Idiopathic pulmonary hemosiderosis: spectrum of thoracic imaging findings in the adult patient. Clin Radiol. 2015, 70:459-65. 10.1016/j.crad.2014.11.007

Campbell S, Macafee CA: A case of idiopathic pulmonary haemosiderosis with myocarditis. Arch Dis Child. 1959, 34:218-22. 10.1136/adc.34.175.218

Gauthier WE, Aterman K: Complete left bundle branch block in idiopathic pulmonary hemorrhosis. J Pediatr. 1974, 85:633-8. 10.1016/s0022-3476(74)80505-6

Di Maio DJ, Zeichner MB, Di Maio VJ: Sudden death in a woman with unsuspected idiopathic pulmonary hemosiderosis. JAMA. 1968, 206:2520-2. 10.1001/jama.206.11.2520

Frustaci A, Cuoco L, Chimenti C, et al.: Celiac disease associated with autoimmune myocarditis. Circulation. 2002, 105:261-8. 10.1161/01.cir.0000017880.86166.87

Neto T, Faleschini E, Tommassini A, et al.: Celiac disease in patients with sporadic and inherited cardiomyopathies and in their relatives. Eur Heart J. 2005, 24:1455-61. 10.1093/eurheartj/ehi136

Rashid M, Lee J: Serologic testing in celiac disease. Can Fam Physician. 2016, 62:58-65.

Marsh MN, Crowe PT: Morphology of the mucosal lesion in gluten sensitivity. Baillieres Clin Gastroenterol. 1995, 9:275-93. 10.1016/0959-3528(95)90032-2

Oberhuber G, Granditsch G, Vogelsang H: The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol. 1999, 11:1185-94. 10.1097/00004277-199911000-00019

Milman N, Pedersen FM: Idiopathic pulmonary hemosiderosis. Epidemiology, pathogenic aspects and diagnosis. Respir Med. 1998, 92:902-7. 10.1016/s0954-6111(98)00188-3

Babiak A, Hetzel J, Krishna G, Fritz P, Moeller P, Balli T, Hetzel M: Transbronchial cryobiopsy: a new tool for lung biopsies. Respiration. 2009, 78:203-8. 10.1159/000203987

Saha BK, Milman NT: Idiopathic pulmonary hemosiderosis: a review of the treatments used during the past 30 years and future directions. Clin Rheumatol. 2021, 40:2547-57. 10.1007/s00024-020-05507-4

Saha BK, Milman NT: Short Review of Liposteroid: A Novel Targeted Glucocorticoid Preparation for
101. Xu LH, Ou RQ, Wu BJ, Wang HY, Fang JP, Tan WP: Corticosteroid in combination with leflunomide and mesenchymal stem cells for treatment of pediatric idiopathic pulmonary hemosiderosis. J Trop Pediatr. 2017, 63:389-94. 10.1093/tropej/fmx002

102. Doi T, Ohga S, Ishimura M, et al.: Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis. Eur J Pediatr. 2015, 172:1475-81. 10.1007/s00431-015-2065-9